Chief Legal Officer · NEUROCRINE BIOSCIENCES INC (NBIX)

Darin Lippoldt

A named executive officer of NEUROCRINE BIOSCIENCES in every fiscal year CompBrief holds from FY2020 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,721,196

Salary $548,730Stock awards $1,550,136Bonus $315,520

FY2021: $5,590,161

5th of 5 named executive officers at Neurocrine Biosciences by FY2022 total.

5 named officers on file for NEUROCRINE BIOSCIENCES, FY2022

Darin Lippoldt’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 3 equity grants, each cited to its filing
  • NBIX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how NEUROCRINE BIOSCIENCES’s whole pay program stands against its peers

  • NEUROCRINE BIOSCIENCES’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NBIX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 5, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Darin Lippoldt’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Darin Lippoldt compensation by year

NEUROCRINE BIOSCIENCES Summary Compensation Table · all 3 fiscal years held
In US dollars, as NEUROCRINE BIOSCIENCES reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021FY2022
Salary$486,200$525,100$548,730
Bonus$170,170$262,550$315,520
Stock awards$2,312,780$2,312,606$1,550,136
Option awards$2,437,508$2,437,544$2,250,049
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$45,704$52,361$56,761
Total$5,452,362$5,590,161$4,721,196

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NEUROCRINE BIOSCIENCES INC DEF 14A filed April 5, 2023, accession 0000914475-23-000032, and prior-year filings. Open the filing on EDGAR.

How this page was built: the NEUROCRINE BIOSCIENCES INC filed document, accession 0000914475-23-000032. Every figure is read from that document and cited to the page and table it appears in. Filed April 5, 2023.

$5.5M
$5.6M
$4.7M
FY20
FY21
FY22
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
PSU12,752$1,523,099—
PSU10,125$1,209,330—
RSU9,492$1,133,724—
RSU5,181$618,819—
RSU3,949$471,669—
RSU2,892$345,420—
Option2,604—$81.05
Option14,538—$102.90
Option24,671—$117.63
Option51,172—$79.02

Per the Outstanding Equity Awards at Fiscal Year-End table in NEUROCRINE BIOSCIENCES INC's FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

51 Form 4 lines since the FY2022 proxy (filed April 5, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-09-11Grant or award—4,483$0.0059,212
2026-09-11Tax withholding—2,419$156.2256,793
2026-07-09Exercise or conversion10b5-110,000$81.4964,729
2026-07-09Sale10b5-110,000$179.6054,729
2026-07-09Exercise or conversion derivative10b5-110,000$0.004,965
2026-06-29Exercise or conversion10b5-18,110$81.4962,839
2026-06-29Exercise or conversion10b5-11,690$81.4956,419
2026-06-29Exercise or conversion derivative10b5-18,110$0.0016,655

The 8 most recent of 51 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

NEUROCRINE BIOSCIENCES’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Kevin C. GormanChief Executive Officer$11,902,527
Eiry RobertsChief Medical Officer$5,735,281
Kyle W. GanoChief Business Development and Strategy Officer$5,421,657
Matthew C. AbernethyChief Financial Officer$4,924,323
Darin Lippoldt · this pageChief Legal Officer$4,721,196

The full NEUROCRINE BIOSCIENCES compensation record

free company brief

This page is one person within NEUROCRINE BIOSCIENCES's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the NEUROCRINE BIOSCIENCES proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NEUROCRINE BIOSCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Darin Lippoldt's compensation dossier · One-time report. No refunds.